{
    "clinical_study": {
        "@rank": "56915", 
        "arm_group": [
            {
                "arm_group_label": "PEG-interferon-alfa 2A", 
                "arm_group_type": "Active Comparator", 
                "description": "PEG-interferon-alfa 2A"
            }, 
            {
                "arm_group_label": "Nucleosides", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Nucleosides"
            }
        ], 
        "brief_summary": {
            "textblock": "This study proposes to compare the effect of 48  weeks exposure to pegylated interferon\n      alpha vs. nucleoside analogue (NA) on hepatitis B e antigen (HBeAg) seroconversion and HBsAg\n      levels in nucleoside analogue controlled HBeAg-positive chronic hepatitis B (CHB) patients\n      who have an undetectable hepatitis B virus (HBV) viral load at least 1 years."
        }, 
        "brief_title": "HBsAg Decline After Pegylated-interferon-\u03b1 in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pegylated interferon after long term NA therapy will potentiate the antiviral efficacy\n      directly via its effect on broad antiviral activities and indirectly via activation of\n      innate and adaptive immune responses leading to HBeAg seroconversion and eventually HBsAg\n      loss and/or seroconversion.\n\n      This study proposes to compare the effect of 48  weeks exposure to pegylated interferon\n      alpha vs. NA on HBeAg seroconversion and HBsAg levels in NA controlled HBeAg-positive CHB\n      patients who have an undetectable HBV viral load at least 1 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent\n\n          -  Age over 20 years\n\n          -  HBeAg-positive CHB patients\n\n          -  Patients treated with all available nucleoside analogue monotherapy or combination in\n             Korea except telbivudine ( e.g.entecavir monotherapy or lamivudine/adefovir\n             combination , lamivudine, adefovir monotherapy) for \u2265 18months and patients who have\n             undetectable HBV viral load at least one year HBV DNA undetectable (\u2264 400 copies/ml )\n             Serum alanine transferase: \u2264 10 X upper limit of normal (ULN) Baseline HBsAg: \u2265 102\n             IU/ml\n\n          -  Negative urine or serum pregnancy test (for women of childbearing potential)\n             documented within the 24-hour period prior to the first dose of test drug.\n             Additionally, all fertile males with partners of childbearing age and females must be\n             using reliable contraception during the study and for 3 months after treatment\n             completion.\n\n          -  Obtaining written informed consent form\n\n        Exclusion Criteria:\n\n          -  Decompensated cirrhosis or other contraindications to interferon alfa 2a therapy\n             following local label.\n\n          -  Concomitant or prior use of telbivudine.\n\n          -  Positive test at screening for hepatitis A virus immunoglobulin M Ab, Hepatitis C\n             virus-RNA or hepatitis C virus Ab, hepatitis delta virus Ab or HIV Ab.\n\n          -  Diagnosed hepatic cellular carcinoma\n\n          -  Any evidence of decompensated liver disease (Childs B-C)\n\n          -  History or other evidence of a medical condition associated with chronic liver\n             disease (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin\n             exposures, thalassemia).\n\n          -  Women with ongoing pregnancy or who are breast feeding.\n\n          -  Evidence of alcohol and/or drug abuse within one year of entry.\n\n          -  History of major organ transplantation with an existing functional graft.\n\n          -  Inability or unwillingness to provide informed consent or abide by the requirements\n             of the study.\n\n          -  History or other evidence of severe illness or any other conditions which would make\n             the patient, in the opinion of the investigator, unsuitable for the study.\n\n          -  Patients with a value of alpha-fetoprotein >100 ng/mL are excluded, unless stability\n             (less than 10% increase) has been documented over at least the previous 3 months.\n\n          -  patients having hypersensitivities for peginterferon alfa-2a or NAs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769833", 
            "org_study_id": "ML25659"
        }, 
        "intervention": [
            {
                "arm_group_label": "PEG-interferon-alfa 2A", 
                "description": "Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly", 
                "intervention_name": "PEG-interferon-Alfa-2A", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys (PEG-interferon-Alfa-2A)"
            }, 
            {
                "arm_group_label": "Nucleosides", 
                "intervention_name": "Nucleosides", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HBsAg", 
            "Chronic hepatitis B", 
            "PEGinterferon Alfa-2A"
        ], 
        "lastchanged_date": "January 16, 2013", 
        "location": {
            "contact": {
                "email": "jheo@pusan.ac.kr", 
                "last_name": "Jeong Heo, Dr", 
                "phone": "+ 82-51-240-7970"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Pusan National University Hospital"
            }, 
            "investigator": {
                "last_name": "Jeong Heo, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "HBsAg Decline and HBeAg Seroconversion Following 48 Weeks Peg-interferon-\u03b1 Treatment in Patients With e Antigen Positive Chronic Hepatitis B After Nucleoside Analogue Maintenance Therapy Compared to Continuing Nucleoside Analogue Treatment", 
        "other_outcome": {
            "description": "To evaluate the effect of immune modulator therapy on the innate immune response in patients with HBeAg-positive CHB in whom NA treatment has resulted in undetectable viral replication.", 
            "measure": "effect of immune modulator therapy on the innate immune response in patients with HBeAg-positive CHB", 
            "safety_issue": "No", 
            "time_frame": "48 week, 96 week"
        }, 
        "overall_contact": {
            "email": "jheo@pusan.ac.kr", 
            "last_name": "Jeong Heo, Dr", 
            "phone": "+ 82-51-240-7970"
        }, 
        "overall_official": {
            "affiliation": "Pusan National University Hospital", 
            "last_name": "Jeong Heo, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate whether pegylated-IFN\u03b12a treatment lowers HBsAg levels and  eventually leads to HBsAg loss in patients after long term NA therapy compared to continuing NA treatment.", 
            "measure": "Change in log10 HBsAg titer during antiviral therapy", 
            "safety_issue": "No", 
            "time_frame": "48 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769833"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HBV DNA undetectability and below 400 IU/mL during antiviral therapy and follow-up", 
                "safety_issue": "No", 
                "time_frame": "48 week, 96 week"
            }, 
            {
                "measure": "HBeAg seroconversion and loss during antiviral therapy  and at end of treatment and 1 and 2 years following end of treatment", 
                "safety_issue": "No", 
                "time_frame": "48 week, 96 week"
            }, 
            {
                "measure": "HBsAg loss and HBsAg seroconversion at end of treatment and 1 and 2 years following end of treatment", 
                "safety_issue": "No", 
                "time_frame": "48 week, 96 week"
            }, 
            {
                "measure": "Change in log10 HBsAg titer during follow-up", 
                "safety_issue": "No", 
                "time_frame": "48 week, 96 week"
            }, 
            {
                "measure": "Mean change in log10 HBsAg titre over time, as estimated from the area between the baseline value and the curve of log10 HBsAg titre divided by the duration of treatment", 
                "safety_issue": "No", 
                "time_frame": "48 week"
            }
        ], 
        "source": "Pusan National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pusan National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}